The functional disorders caused by central nervous system (CNS) diseases, such as ischemic stroke, are clinically incurable and current treatments have limited effects. Previous studies suggested that cell-based therapy using mesenchymal stem cells (MSCs) exerts therapeutic effects for ischemic stroke. In addition, the characteristics of MSCs may depend on their sources. Among the derived tissues of MSCs, we have focused on cranial bones originating from the neural crest. We previously demonstrated that the neurogenic potential of human cranial bone-derived MSCs (cMSCs) was higher than that of human iliac bone-derived MSCs. Therefore, we presumed that cMSCs have a higher therapeutic potential for CNS diseases. However, the therapeutic effects of cMSCs have not yet been elucidated in detail. In the present study, we aimed to demonstrate the therapeutic effects of transplantation with rat cranial bone-derived MSCs (rcMSCs) in ischemic stroke model rats. The mRNA expression of brain-derived neurotrophic factor and nerve growth factor was significantly stronger in rcMSCs than in rat bone marrow-derived MSCs (rbMSCs). Ischemic stroke model rats in the rcMSC transplantation group showed better functional recovery than those in the no transplantation and rbMSC transplantation groups. Furthermore, in the in vitro study, the conditioned medium of rcMSCs significantly suppressed the death of neuroblastoma × glioma hybrid cells (NG108-15) exposed to oxidative and inflammatory stresses. These results suggest that cMSCs have potential as a candidate cell-based therapy for CNS diseases.
Get full access to this article
View all access options for this article.
References
1.
BaoX, WeiJ, FengM, LuS, LiG, DouW, MaW, MaS, AnY, et al. (2011). Transplantation of human bone marrow-derived mesenchymal stem cells promotes behavioral recovery and endogenous neurogenesis after cerebral ischemia in rats. Brain Res, 1367:103–113.
2.
BhasinA, SrivastavaMV, MohantyS, BhatiaR, KumaranSS and BoseS. (2013). Stem cell therapy: a clinical trial of stroke. Clin Neurol Neurosurg, 115:1003–1008.
3.
CuiX, ChoppM, ZacharekA, DaiJ, ZhangC, YanT, NingR, RobertsC, ShehadahA, et al. (2012). Combination treatment of stroke with sub-therapeutic doses of simvastatin and human umbilical cord blood cells enhances vascular remodeling and improves functional outcome. Neuroscience, 227:223–231.
4.
GuoF, LvS, LouY, TuW, LiaoW, WangY and DengZ. (2012). Bone marrow stromal cells enhance the angiogenesis in ischaemic cortex after stroke: involvement of notch signalling. Cell Biol Int, 36:997–1004.
5.
IkegameY, YamashitaK, HayashiS, MizunoH, TawadaM, YouF, YamadaK, TanakaY, EgashiraY, et al. (2011). Comparison of mesenchymal stem cells from adipose tissue and bone marrow for ischemic stroke therapy. Cytotherapy, 13:675–685.
6.
MunozJR, StoutengerBR, RobinsonAP, SpeesJL and ProckopDJ. (2005). Human stem/progenitor cells from bone marrow promote neurogenesis of endogenous neural stem cells in the hippocampus of mice. Proc Natl Acad Sci U S A, 102:18171–18176.
7.
ChenJ, LiY, KatakowskiM, ChenX, WangL, LuD, LuM, GautamSC and ChoppM. (2003). Intravenous bone marrow stromal cell therapy reduces apoptosis and promotes endogenous cell proliferation after stroke in female rat. J Neurosci Res, 73:778–786.
8.
LiY, ChenJ, ChenXG, WangL, GautamSC, XuYX, KatakowskiM, ZhangLJ, LuM, JanakiramanN and ChoppM. (2002). Human marrow stromal cell therapy for stroke in rat: neurotrophins and functional recovery. Neurology, 59:514–523.
9.
LiuZ, LiY, ZhangRL, CuiY and ChoppM. (2011). Bone marrow stromal cells promote skilled motor recovery and enhance contralesional axonal connections after ischemic stroke in adult mice. Stroke, 42:740–744.
10.
PetersonDA. (2004). Umbilical cord blood cells and brain stroke injury: bringing in fresh blood to address an old problem. J Clin Invest, 114:312–314.
11.
YooS-W, KimSS, LeeS-Y, LeeH-S, KimHS, LeeY-D and Suh-KimH. (2008). Mesenchymal stem cells promote proliferation of endogenous neural stem cells and survival of newbone cells in a rat stroke model. Exp Mol Med, 40:387–397.
12.
SmithHK and GavinsFN. (2012). The potential of stem cell therapy for stroke: is PISCES the sign?. FASEB J, 26:2239–2252.
13.
JeongCH, KimSM, LimJY, RyuCH, JunJA and JeunSS. (2014). Mesenchymal stem cells expressing brain-derived neurotrophic factor enhance endogenous neurogenesis in an ischemic stroke model. BioMed Res Int, 2014:129145.
14.
KurozumiK, NakamuraK, TamiyaT, KawanoY, IshiiK, KobuneM, HiraiS, UchidaH, SasakiK, et al. (2005). Mesenchymal stem cells that produce neurotrophic factors reduce ischemic damage in the rat middle cerebral artery occlusion model. Mol Ther, 11:96–104.
15.
LeeSH, JinKS, BangOY, KimBJ, ParkSJ, LeeNH, YooKH, KooHH and SungKW. (2015). Differential migration of mesenchymal stem cells to ischemic regions after middle cerebral artery occlusion in rats. PLoS One, 10:e0134920.
16.
LiG, YuF, LeiT, GaoH, LiP, SunY, HuangH and MuQ. (2016). Bone marrow mesenchymal stem cell therapy in ischemic stroke: mechanisms of action and treatment optimization strategies. Neural Regen Res, 11:1015–1024.
17.
KisielAH, McDuffeeLA, MasaoudE, BaileyTR, Esparza GonzalezBP and Nino-FongR. (2012). Isolation, characterization, and in vitro proliferation of canine mesenchymal stem cells derived from bone marrow, adipose tissue, muscle, and periosteum. Am J Vet Res, 73:1305–1317.
18.
HermannA, GastlR, LiebauS, PopaMO, FiedlerJ, BoehmBO, MaiselM, LercheH, SchwarzJ, BrennerR and StorchA. (2004). Efficient generation of neural stem cell-like cells from adult human bone marrow stromal cells. J Cell Sci, 117:4411–4422.
19.
MeliefSM, ZwagingaJJ, FibbeWE and RoelofsH. (2013). Adipose tissue-derived multipotent stromal cells have a higher immunomodulatory capacity than their bone marrow-derived counterparts. Stem Cells Transl Med, 2:455–463.
20.
ReichCM, RaabeO, WenischS, BridgerPS, KramerM and ArnholdS. (2012). Isolation, culture and chondrogenic differentiation of canine adipose tissue- and bone marrow-derived mesenchymal stem cells—a comparative study. Vet Res Commun, 36:139–148.
21.
SadlerTW. (2010). The embryologic origin of ventral body wall defects. Semin Pediatr Surg, 19:209–214.
22.
CalioML, MarinhoDS, KoGM, RibeiroRR, CarbonelAF, OyamaLM, OrmanjiM, GuiraoTP, CalioPL, et al. (2014). Transplantation of bone marrow mesenchymal stem cells decreases oxidative stress, apoptosis, and hippocampal damage in brain of a spontaneous stroke model. Free Radic Biol Med, 70:141–154.
23.
HonmouO, HoukinK, MatsunagaT, NiitsuY, IshiaiS, OnoderaR, WaxmanSG and KocsisJD. (2011). Intravenous administration of auto serum-expanded autologous mesenchymal stem cells in stroke. Brain, 134:1790–1807.
24.
SasakiY, SasakiM, Kataoka-SasakiY, NakazakiM, NagahamaH, SuzukiJ, TateyamaD, OkaS, NamiokaT, et al. (2016). Synergic effects of rehabilitation and intravenous infusion of mesenchymal stem cells After stroke in rats. Phys Ther, 96:1791–1798.
25.
YangB, XiX, AronowskiJ and SavitzSI. (2012). Ischemic stroke may activate bone marrow mononuclear cells to enhance recovery after stroke. Stem Cells Dev, 21:3332–3340.
26.
SakaiK, YamamotoA, MatsubaraK, NakamuraS, NaruseM, YamagataM, SakamotoK, TauchiR, WakaoN, et al. (2012). Human dental pulp-derived stem cells promote locomotor recovery after complete transection of the rat spinal cord by multiple neuro-regenerative mechanisms. J Clin Invest, 122:80–90.
27.
ShinagawaK, MitsuharaT, OkazakiT, TakedaM, YamaguchiS, MagakiT, OkuraY, UwatokoH, KawaharaY, YugeL and KurisuK. (2015). The characteristics of human cranial bone marrow mesenchymal stem cells. Neurosci Lett, 606:161–166.
28.
Gutierrez-FernandezM, Rodriguez-FrutosB, Ramos-CejudoJ, Vallejo-CremadesMT, FuentesB, CerdanS and Diez-TejedorE. (2013). Effects of intravenous administration of allogenic bone marrow- and adipose tissue-derived mesenchymal stem cells on functional recovery and brain repair markers in experimental ischemic stroke. Stem Cell Res Ther, 4:11.
29.
PavlichenkoN, SokolovaI, VijdeS, ShvedovaE, AlexandrovG, KrouglyakovP, FedotovaO, GilerovichEG, PolyntsevDG and OtellinVA. (2008). Mesenchymal stem cells transplantation could be beneficial for treatment of experimental ischemic stroke in rats. Brain Res, 1233:203–213.
30.
SekineY, HatanakaR, WatanabeT, SonoN, IemuraS, NatsumeT, KuranagaE, MiuraM, TakedaK and IchijoH. (2012). The Kelch repeat protein KLHDC10 regulates oxidative stress-induced ASK1 activation by suppressing PP5. Mol Cell, 48:692–704.
31.
ImuraT, TomiyasuM, OtsuruN, NakagawaK, OtsukaT, TakahashiS, TakedaM, LoonivaS, KawaharaY, et al. (2017). Hypoxic preconditioning increases the neuroprotective effects of mesenchymal stem cells in a rat model of spinal cord injury. J Stem Cell Res Ther, 7:375.
32.
NeirinckxV, AgirmanG, CosteC, MarquetA, DionV, RogisterB, FranzenR and WisletS. (2015). Adult bone marrow mesenchymal and neural crest stem cells are chemoattractive and accelerate motor recovery in a mouse model of spinal cord injury. Stem Cell Res Ther, 6:211.
33.
PomiesP, BlaquiereM, MauryJ, MercierJ, GouziF and HayotM. (2016). Involvement of the FoxO1/MuRF1/Atrogin-1 signaling pathway in the oxidative stress-induced atrophy of cultured chronic obstructive pulmonary disease myotubes. PLoS One, 11:e0160092.
34.
VisserM, ZubakovD, BallantyneKN and KayserM. (2011). mRNA-based skin identification for forensic applications. Int J Legal Med, 125:253–263.
35.
ZhaoH, FengJ, HoTV, GrimesW, UrataM and ChaiY. (2015). The suture provides a niche for mesenchymal stem cells of craniofacial bones. Nat Cell Biol, 17:386–396.
36.
BroughtonBR, ReutensDC and SobeyCG. (2009). Apoptotic mechanisms after cerebral ischemia. Stroke, 40:e331–e339.
37.
ChoppM and LiY. (2002). Treatment of neural injury with marrow stromal cells. Lancet Neurol, 1:92–100.
38.
KimEY, LeeKB, YuJ, LeeJH, KimKJ, HanKW, ParkKS, LeeDS and KimMK. (2014). Neuronal cell differentiation of mesenchymal stem cells originating from canine amniotic fluid. Hum Cell, 27:51–58.
39.
LeiteC, SilvaNT, MendesS, RibeiroA, de FariaJP, LourencoT, dos SantosF, AndradePZ, CardosoCM, et al. (2014). Differentiation of human umbilical cord matrix mesenchymal stem cells into neural-like progenitor cells and maturation into an oligodendroglial-like lineage. PLoS One, 9:e111059.
40.
LongX, OlszewskiM, HuangW and KletzelM. (2005). Neural cell differentiation in vitro from adult human bone marrow mesenchymal stem cells. Stem Cells Dev, 14:65–69.
41.
OkolicsanyiRK, CamilleriET, OikariLE, YuC, CoolSM, van WijnenAJ, GriffithsLR and HauptLM. (2015). Human mesenchymal stem cells retain multilineage differentiation capacity including neural marker expression after extended in vitro expansion. PLoS One, 10:e0137255.
42.
TaranR, MamidiMK, SinghG, DuttaS, ParharIS, JohnJP, BhondeR, PalR and DasAK. (2014). In vitro and in vivo neurogenic potential of mesenchymal stem cells isolated from different sources. J Biosci, 39:157–169.
43.
CossettiC, Alfaro-CervelloC, DonegaM, TyzackG and PluchinoS. (2012). New perspectives of tissue remodelling with neural stem and progenitor cell-based therapies. Cell Tissue Res, 349:321–329.
44.
LeesJS, SenaES, EganKJ, AntonicA, KoblarSA, HowellsDW and MacleodMR. (2012). Stem cell-based therapy for experimental stroke: a systematic review and meta-analysis. Int J Stroke, 7:582–588.
45.
ParrAM, TatorCH and KeatingA. (2007). Bone marrow-derived mesenchymal stromal cells for the repair of central nervous system injury. Bone Marrow Transplant, 40:609–619.
46.
PluchinoS and CossettiC. (2013). How stem cells speak with host immune cells in inflammatory brain diseases. Glia, 61:1379–1401.
47.
BarkerRA, JainM, ArmstrongRJ and CaldwellMA. (2003). Stem cells and neurological disease. J Neurol Neurosurg Psychiatry, 74:553–557.
48.
CaplanAI and DennisJE. (2006). Mesenchymal stem cells as trophic mediators. J Cell Biochem, 98:1076–1084.
49.
JiangY, WeiN, LuT, ZhuJ, XuG and LiuX. (2011). Intranasal brain-derived neurotrophic factor protects brain from ischemic insult via modulating local inflammation in rats. Neuroscience, 172:398–405.
50.
PloughmanM, WindleV, MacLellanCL, WhiteN, DoreJJ and CorbettD. (2009). Brain-derived neurotrophic factor contributes to recovery of skilled reaching after focal ischemia in rats. Stroke, 40:1490–1495.
MatsudaS, FujitaT, KajiyaM, KashiwaiK, TakedaK, ShibaH and KuriharaH. (2015). Brain-derived neurotrophic factor prevents the endothelial barrier dysfunction induced by interleukin-1beta and tumor necrosis factor-alpha. J Periodont Res, 50:444–451.
53.
TakedaK, KermaniP, AnastasiaA, ObinataY, HempsteadBL and KuriharaH. (2013). BDNF protects human vascular endothelial cells from TNFalpha-induced apoptosis. Biochem Cell Biol, 91:341–349.
54.
LiuZ, MaD, FengG, MaY and HuH. (2007). Recombinant AAV-mediated expression of human BDNF protects neurons against cell apoptosis in Abeta-induced neuronal damage model. J Huazhong Univ Sci Technol Med Sci, 27:233–236.
55.
GueganC, OntenienteB, MakiuraY, Merad-BoudiaM, Ceballos-PicotI and SolaB. (1998). Reduction of cortical infarction and impairment of apoptosis in NGF-transgenic mice subjected to permanent focal ischemia. Brain Res Mol Brain Res, 55:133–140.
56.
LukYO, ChenWY, WongWJ, HuHH, HsuLC, ChernCM, HuangKJ and LawSL. (2004). Treatment of focal cerebral ischemia with liposomal nerve growth factor. Drug Deliv, 11:319–324.
57.
ZhuW, ChengS, XuG, MaM, ZhouZ, LiuD and LiuX. (2011). Intranasal nerve growth factor enhances striatal neurogenesis in adult rats with focal cerebral ischemia. Drug Deliv, 18:338–343.
58.
SekineY, HatanakaR, WatanabeT, SonoN, IemuraS, NatsumeT, KuranagaE, MiuraM, TakedaK and IchijoH. (2012). The Kelch repeat protein KLHDC10 regulates oxidative stress-induced ASK1 activation by suppressing PP5. Mol Cell, 48:692–704.
59.
KirklandRA, SaavedraGM and FranklinJL. (2007). Rapid activation of antioxidant defenses by nerve growth factor suppresses reactive oxygen species during neuronal apoptosis: evidence for a role in cytochrome c redistribution. J Neurosci, 27:11315–11326.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
